Kind Pharmaceutical's AND017, a first-in-class hemoglobin elevating agent (HbEA), is set to be presented at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego. The late-breaking abstract highlights the Phase 2 clinical trial results of AND017 in treating anemia in dialysis-dependent chronic kidney disease (DD-CKD).
The presentation will cover the efficacy and safety of AND017 in DD-CKD patients. AND017 targets multiple stages of the red blood cell (RBC) life cycle and is being developed to treat anemia associated with various disorders, including DD-CKD, non-dialysis dependent chronic kidney disease (NDD-CKD), cancer-related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia.
ASN Kidney Week Presentations
In addition to the late-breaking abstract, KIND will present three other posters detailing results from the AND017 Phase 1 trial in healthy volunteers and the Phase 2 trial in NDD-CKD patients. All presentations are scheduled for Thursday, October 24, from 10:00 am to 12:00 pm PDT.
- Efficacy and Safety of AND017 for Treatment of Anemia in Dialysis-Dependent CKD (Abstract #4176548, Poster Board #TH-PO1181)
- First-in-Human Study of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) AND017 in Healthy Participants (Abstract #4122116, Poster Board #TH-PO896)
- Effect of Food on the Pharmacokinetics of AND017 in a Phase I Study (Abstract #4122852, Poster Board #TH-PO897)
- Safety and Efficacy of AND017, a Hypoxia Inducible Factor-Prolyl-Hydroxylase Inhibitor (HIF-PHI), in patients with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (Abstract #4124344, Poster Board #TH-PO898)
About AND017
AND017 is designed to elevate hemoglobin levels by acting on multiple stages of red blood cell development. It is currently under development for a range of anemia-related conditions, marking a potential advancement in the treatment landscape for patients with anemia associated with chronic kidney disease and other hematological disorders.
